Pacira BioSciences Management

Management Kriterienprüfungen 2/4

Pacira BioSciences' CEO ist Frank Lee , ernannt in Jan 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.23% der Aktien des Unternehmens, im Wert von $1.34M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.9 Jahre bzw. 4.9 Jahre.

Wichtige Informationen

Frank Lee

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5yrs

Jüngste Management Updates

Recent updates

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Sep 06

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Jul 23

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

Geschäftsführer

Frank Lee (56 yo)

less than a year

Amtszeit

Mr. Frank D. Lee served as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021 until September 2024. He is Independent Director of Bausch Health Companies Inc. from May 14, 2024. He i...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Charles Reinhart	Chief Financial Officer	8.3yrs	US$1.43m	0.059% $ 398.7k
Daryl Gaugler	Chief Operating Officer	2.3yrs	US$1.53m	0.027% $ 178.1k
Kristen Williams	Chief Administrative Officer & Secretary	9.9yrs	US$1.60m	0% $ 0
David Stack	Advisor	less than a year	US$6.88m	0.51% $ 3.4m
Jonathan Slonin	Chief Medical Officer	3.2yrs	US$1.59m	0.028% $ 188.7k
Frank Lee	CEO & Director	less than a year	keine Daten	0.018% $ 120.2k
Lauren Riker	Principal Accounting Officer & Senior VP of Finance	12.5yrs	US$288.82k	0.0046% $ 31.1k
Susan Mesco	Head of Investor Relations	no data	keine Daten	keine Daten
Anthony Molloy	Chief Legal & Compliance Officer	2.8yrs	US$2.05m	0.028% $ 187.3k
Richard Kahr	Vice President of Human Resources	9.2yrs	keine Daten	keine Daten
Christopher Young	Chief Manufacturing Officer	1.4yrs	keine Daten	keine Daten

3.0yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: PCRXDas Führungsteam des Unternehmens gilt als erfahren (2.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Frank Lee	CEO & Director	less than a year	keine Daten	0.018% $ 120.2k
Laura Brege	Independent Director	13.3yrs	US$364.01k	0.027% $ 179.1k
Paul Hastings	Chairman of the Board	13.3yrs	US$390.51k	0.016% $ 109.0k
Andreas Wicki	Independent Director	17.8yrs	keine Daten	keine Daten
Mark Kronenfeld	Independent Director	11.3yrs	US$373.01k	0.043% $ 286.0k
Christopher Christie	Independent Director	5yrs	US$325.01k	0.011% $ 76.5k
Alethia Young	Independent Director	less than a year	US$427.86k	0% $ 0
Marcelo Bigal	Independent Director	less than a year	US$426.45k	0.011% $ 71.4k
Abraham Ceesay	Independent Director	less than a year	US$427.16k	0% $ 0
Mark Froimson	Independent Director	7.3yrs	US$349.01k	0.020% $ 134.4k
Michael Yang	Independent Director	less than a year	US$427.16k	0.0043% $ 29.1k

5.0yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: PCRXDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Pacira BioSciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Pacira Biosciences, Inc. Announces Board Changes

CEO & Director recently bought US$100k worth of stock

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Recent updates

DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences

Investor sentiment improves as stock rises 15%

Pacira Biosciences, Inc. Announces Board Changes

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Investor sentiment deteriorates as stock falls 44%

CEO & Director recently bought US$100k worth of stock

Price target decreased by 46% to US$20.83

New major risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 20%

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales